Olix Pharmaceuticals Inc. (226950) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Olix Pharmaceuticals Inc. (226950:KRX), powered by AI.
- Current Price
- ₩120,800
- P/E Ratio
- -155.9
- Market Cap
- 2.5T
- Sector
- Healthcare
What is the Olix Pharmaceuticals Inc. stock price forecast?
Olix Pharmaceuticals Inc. is currently trading at ₩120,800. View real-time AI analysis on Alpha Lenz.
What is Olix Pharmaceuticals Inc. insider trading activity?
View the latest insider trading data for Olix Pharmaceuticals Inc. on Alpha Lenz.
What is Olix Pharmaceuticals Inc.'s P/E ratio?
Olix Pharmaceuticals Inc.'s P/E ratio is -155.9.
Olix Pharmaceuticals Inc.
KRX · 226950“Olix Pharmaceuticals Inc. trades at a P/E of -155.9 (undervalued) with modest ROE of -18.8%. 3Y revenue CAGR of 16.3% highlights clear growth momentum.”
Ask for details →Company Overview
Olix Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research and development of RNA interference (RNAi) therapeutics. The company's primary focus is on creating innovative drug solutions aimed at silencing disease-causing genes, which has the potential to treat a wide range of genetic disorders and other challenging health conditions. Olix leverages its proprietary asymmetric RNAi technology, which differentiates it in the biotechnology sector by offering enhanced stability and efficacy compared to traditional siRNA approaches. Operating chiefly in the healthcare and life sciences industry, Olix Pharmaceuticals collaborates with academic institutions and global pharmaceutical companies to advance its therapeutic pipeline. The firm's work underscores a significant advancement in personalized medicine, aiming to offer targeted therapies for conditions that have been traditionally difficult to treat. Through its pioneering research, Olix Pharmaceuticals plays a vital role in transforming treatment paradigms and contributing to the evolving landscape of biotechnological innovations.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Olix Pharmaceuticals Inc. trades at a P/E of -155.9 (undervalued) with modest ROE of -18.8%. 3Y revenue CAGR of 16.3% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Olix Pharmaceuticals Inc. (ticker: 226950) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 66 employees. Market cap is $2.5T.
The current price is ₩120,800 with a P/E ratio of -155.94x and P/B of 16.43x.
ROE is -18.83% and operating margin is -204.35%. Annual revenue is $14.7B.